Gains:
- Multiple testing correction (corrected p-value) in differential expression analysis and the ability to correctly interpret fold change and avoid false positives
- Detecting the batch effect and adding it to the model with PCA and separating technical noise from biological difference
- Ability to link each pathway identity to the source and control it with biological consistency in pathway enrichment and multi-omics integration
A cell is not a single number; It is a system where thousands of genes, proteins and metabolites dance simultaneously. Omics (the collective name for approaches that measure a biological layer as a whole) tries to capture this entire dance: genomics (DNA), transcriptomics (RNA — which genes work and how much), proteomics (proteins), metabolomics (small molecules). Each omics layer produces thousands of dimensional, noisy and costly data. AI is powerful at scanning this high-dimensional data and marking patterns; But you are the one who decides which pattern is biological truth and which is technical noise.
In this unit, we will proceed through transcriptomics, the most common omics analysis; The principles apply to other layers as well. Typical workflow: expression matrix from raw data (rows are genes, columns are samples, cells are expression levels), normalization (removing technical differences), differential expression analysis (finding genes that change significantly between two conditions), pathway enrichment (finding which biological pathways the changed genes are clustered in) and interpretation.
Differential expression: fold change and corrected p-value
To tell if a gene has “changed,” two numbers are looked at: fold change — how many times expression increases/decreases, usually on a log2 scale — and adjusted p-value (padj — the statistic that controls for false positives when multiple testing is done). Why fix? Because you test 20,000 genes at the same time; Even by chance, hundreds of genes may turn out to be "significant". Without multiple testing correction—limiting the false discovery rate with methods such as Benjamini-Hochberg—the list is misleading. The AI can write the script that calculates this statistic, but if it omits the correction, your result is scientifically indefensible.
Caution: An AI might say "500 genes changed significantly" based on the raw p-value. Looking at the corrected p-value, the number could drop to 30. Always check the multi-test correction yourself; This is the difference between acceptance and rejection of the publication.
Batch effect: the most insidious trap
Batch effect (technical difference arising from the processing of samples by different days, devices or people) is the biggest source of error in omics analysis. If your two conditions were processed on two different days, the "biological difference" you see may actually be the day difference. The AI may suggest adding the batch variable to the model (e.g. ~ batch + condition), but it is your responsibility to set it up correctly and not mix it up in the experimental design.
Tip: Before starting the analysis, draw a PCA (Principal Component Analysis - a method that summarizes and visualizes high-dimensional data on several axes) chart. If samples are clustered by batch rather than by biological condition, the batch effect is dominant and must be corrected for first.
Multi-omics integration
Real understanding often comes from putting the layers together: if a gene is working harder but its protein is not increasing, regulation is at the translational level. Multi-omics integration—combining different omics layers into a single model—is where AI gets stronger but also where it misleads the most; because the scales, noise and sample matches of the layers are different. AI suggests an integration workflow, but you control the biological consistency of the results.
three mini cases
Case 1 — Enrichment accelerated. 1,240 differential genes were found in a cancer project. AI primed them for pathway enrichment, highlighting cell cycle and DNA repair pathways; The team created a hypothesis map in 2 hours. But they retested each pathway with an independent tool (g:Profiler) and found that one pathway was mismapped by the AI.
Case 2 — Batch trap. One laboratory found a "striking" 900-gene difference between two treatment groups. When they performed PCA, they saw that the samples were separated by sequencing batch. After batch correction, the actual difference decreased to 60 genes. AI had unintentionally omitted the batch variable in the first analysis.
Case 3 — Made-up pathway name. A student gave the gene list to AI and asked, "Which KEGG pathway?" The AI provided a pathway ID and name as if it were real. When the student searched on KEGG, he saw that that ID did not exist; verification prevented a fabricated result.
Four copyable templates
1) DESeq2 workflow outline:
Your role: computational biologist. Write a step-by-step script for RNA-seq differential expression analysis with R/DESeq2: count matrix reading, design formula (~ batch + condition), normalization, result table. EXPRESSLY apply multiple testing correction (BH) and use padjcolumn. Explain what each step does in a comment line.
2) Quality/batch control:
Give me an RNA-seq QC checklist: batch control with PCA, library size, number of gene detections, outlier detection. For each metric, specify a "what I see makes me worried" threshold. Explain what I should do if batch and biological condition are mixed.
3) Enrichment result verification:
I will give you an enriched pathway list (number of pathways, padj, genes). Write down the identity of each pathway (KEGG/GO ID) verbatim and do not make it up. Filter results with padj < 0.05. Specify which pathways biologically support each other, but mark each identity as "must be verified in database."
4) Multi-omics consistency check:
Transcriptomic and proteomic yield conflicting expression directions for a gene/protein pair. List possible biological (post-translation editing) and technical (measurement noise, sample matching) reasons for this and tell me how to test each.
Weak prompt / Strong prompt
Weak prompt:
Name the important pathways in this gene list.
No sources, no statistics, high risk of fabricated pathways.
Powerful prompt:
Your role: computational biologist. In the attached differential gene table(gene, log2FC, padj) only take genes with padj < 0.05. Tell me the steps of a GO enrichment analysis to be performed with these genes and the tool (g:Profiler) I will use. The pathway name is FAKE; I will run the tool and do the analysis, you just describe the correct methodology and multiple testing correction.
Difference: clear filter, methodology focus, ban on fabrication and leaving verification to the user.
Omics analysis steps
step
Purpose
common mistake
AI role
normalization
Eliminate technical difference
Wrong method choice
Script + rationale
PCA/QC
Batch and outlier detection
skip my step
Image + comment
differential expression
Finding changing genes
Uncorrected p
Script draft
enrichment
find a pathway
fabricated pathway
methodology
integration
merge layers
Scale/match error
Workflow recommendation
Single cell omics: a new scale
In recent years, single-cell sequencing — measuring the expression profile of each of thousands of cells separately — has taken omics to a new dimension. Now, instead of "the average expression of a tissue", we can see each cell type within that tissue separately. This power introduces new pitfalls: the data is extremely sparse (most genes have zero reads in most cells—dropout), the size is tens of thousands of cells × twenty-thousands of genes, and separating cell types is mostly done by clustering. AI is powerful at producing clustering and cell type labeling outlines on single cell data; but you verify with known marker genes whether each cluster is a real cell type or a technical artifact (e.g. dead cells, two cells caught together). Do not accept the cell type label suggested by AI without confirming the marker genes of that cluster in the actual literature.
Tip: In a single-cell analysis, if the AI suggests a “T cell” label to a cluster, check for yourself that T cell markers (e.g. CD3) are indeed highly expressed in that cluster. If the label is not supported by the token, it is a hypothesis, not a conclusion.
Common mistakes
- Skipping multiple testing correction. The list swells with raw p-value; padj should be used.
- Mistaking the batch effect for biology. It should be checked first with PCA.
- Making floor change the only criterion. High fold change may be misleading in low-expression, noisy genes.
- Accepting the made-up pathway/GO identity. Every identity must be verified in the database.
- Underestimating the sample size. Statistical power is low in a 2 by 2 design; The results should be interpreted with caution.
In summary
Omics analysis works with high-dimensional, noisy data, and AI accelerates this data by scanning it, writing scripts, and marking patterns. But multiple test correction in differential expression, batch control with PCA and source verification in enrichment are indispensable. Multi-omics integration is powerful but misleading; Check each result with biological consistency, taking into account the scale and noise differences of the layers.
Application task
Find a publicly available RNA-seq count matrix (e.g. from GEO). Have the AI write an analysis script with the "DESeq2 workflow" template and check in code that the multiple testing correction has actually been applied. Then ask the AI for an enrichment comment and verify all the pathway IDs it returns one by one against the KEGG or GO database; Note how many are real.
checklist
- [ ] I used padj (corrected) in the differential analysis, not the raw p-value.
- [ ] I checked the batch effect with PCA and added it to the model if necessary.
- [ ] I interpreted genes with high fold change but low expression with caution.
- [ ] I verified each pathway/GO ID against the real database.
- [ ] I evaluated the statistical power of the sample size.
- [ ] I divided the multi-omics contradictions into biological and technical causes.